Food allergy

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune, humanized) 2 substances
Unknown / small molecule 1 substance
Phase III: 1 Phase II: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Novartis Pharma AG Commercial
    DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS); LIGELIZUMAB
    2022-502366-25-00 5 countries 2023 n=55
    Ended

Phase II

1 trial
  • Hospital Infantil Universitario Nino Jesus Academic
    OMALIZUMAB
    2023-503958-12-00 1 country n=20
    Pending

Phase I (Other)

1 trial
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-511032-27-00 1 country n=3
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Regeneron Pharmaceuticals Inc. Commercial 1 Phase I (Other) 0
Novartis Pharma AG Commercial 1 Phase III 0
Hospital Infantil Universitario Nino Jesus Academic 1 Phase II 0
New trials by year
2023
1
← All indication landscapes